Blis Technologies operations manager Reiner van der Hilst
in the company's manufacturing plant. Photo by Craig
Blis Technologies has opened a new manufacturing plant
within its Birch St premises in Dunedin.
Chief executive Dr Barry Richardson said the ''time was
right'' to establish commercial premises outside the
University of Otago where the company was formed as a
commercialisation of science from within the university.
The company was getting necessary export approvals before the
plant became fully operational.
Blis shares opened at 1.1c on Tuesday and, following the
announcement to the market, reached a high of 2c before
closing at 1.6c. Yesterday, they last traded at 1.7c.
Blis focuses on niche human health markets producing
probiotics targeted specifically at oral health.
It has already built a business supplying ingredients through
its global distributer Novus Nutrition Brands to
manufacturers and marketers in North America, Japan,
Southeast Asia, Taiwan and Europe, Dr Richardson said.
Its retail business was now being broadened with oral
probiotic lozenge formulations being marketed in the Asia
Pacific region and in Europe under its own brand, and
supplied to other companies for marketing under their brands.
Blis had GRAS (generally recognised as safe) approval for the
United States and also approvals for New Zealand and
Australia, as well as China.
Regulatory approval was essential for a food ingredients and
human health business as it determined market access, Dr
It was fortunate the company had a ''sophisticated''
shareholder base that understood what was required to get
that market access.
There was also growth in shareholders and business
connections in China and other key markets were able to
assist with business development in those sectors.
The company targeted opening the plant before a reciprocal
visit by senior executives of China's largest pharmacy group,
Sinopharm, next month. It had been working hard on
establishing the right market channel in China and
Sinopharm's visit was ''an important step on the way'', he
Blis is currently targeting $3.5 million to $4.5 million from
a shareholder purchase plan to offset further short-term
financial losses and progress product sales to Asian markets.